Ieva Kurilova1, Achiude Bendet2, Elena N Petre2, Franz E Boas2, Elena Kaye3, Mithat Gonen4, Anne Covey2, Lynn A Brody2, Karen T Brown2, Nancy E Kemeny5, Hooman Yarmohammadi2, Etay Ziv2, Michael I D'Angelica6, T Peter Kingham6, Andrea Cercek5, Steven B Solomon2, Regina G H Beets-Tan7, Constantinos T Sofocleous8. 1. Department of Radiology, Interventional Radiology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands. 2. Department of Radiology, Interventional Radiology Service, Memorial Sloan Kettering Cancer Center, New York, NY. 3. Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY. 4. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. 5. Department of Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center, New York, NY. 6. Hepatopancreatobiliary Service, Memorial Sloan Kettering Cancer Center, New York, NY. 7. Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands. 8. Department of Radiology, Interventional Radiology Service, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: sofoclec@mskcc.org.
Abstract
INTRODUCTION: The purpose of this study was to identify risk factors associated with local tumor progression-free survival (LTPFS) and complications after colorectal liver metastases (CLM) thermal ablation (TA). PATIENTS AND METHODS: This retrospective analysis included 286 patients with 415 CLM undergoing TA (radiofrequency and microwave ablation) in 378 procedures from January 2003 to July 2017. Prior hepatic artery infusion (HAI), bevacizumab, pre-existing biliary dilatation, ablation modality, minimal ablation margin (MM), prior hepatectomy, CLM number, and size were analyzed as factors influencing complications and LTPFS. Statistical analysis included the Kaplan-Meier method, Cox proportional hazards model, competing risk analysis, univariate/multivariate logistic/exact logistic regressions, and the Fisher exact test. Complications were reported according to modified Society of Interventional Radiology guidelines. RESULTS: The median follow-up was 31 months. There was no LTP for MM > 10 mm. Smaller tumor size, increased MM, and prior hepatectomy correlated with longer LTPFS. The major complications occurred following 28 (7%) of 378 procedures. There were no biliary complications in HAI-naive patients, versus 11% in HAI patients (P < .001), of which 7% were major. Biliary complications predictors in HAI patients included biliary dilatation, bevacizumab, and MM > 10 mm. In HAI patients, ablation with 6 to 10 mm and > 10 mm MM resulted in major biliary complication rates of 4% and 21% (P = .0011), with corresponding LTP rates of 24% and 0% (P = .0033). In HAI-naive patients, the LTP rates for 6 to 10 mm and > 10 mm MM were 27% and 0%, respectively. CONCLUSIONS: No LTP was seen for MM > 10 mm. Biliary complications occurred only in HAI patients, especially in those with biliary dilatation, bevacizumab, and MM > 10 mm. In HAI patients, MM of 6 to 10 mm resulted in 76% local tumor control and 4% major biliary complications incidence.
INTRODUCTION: The purpose of this study was to identify risk factors associated with local tumor progression-free survival (LTPFS) and complications after colorectal liver metastases (CLM) thermal ablation (TA). PATIENTS AND METHODS: This retrospective analysis included 286 patients with 415 CLM undergoing TA (radiofrequency and microwave ablation) in 378 procedures from January 2003 to July 2017. Prior hepatic artery infusion (HAI), bevacizumab, pre-existing biliary dilatation, ablation modality, minimal ablation margin (MM), prior hepatectomy, CLM number, and size were analyzed as factors influencing complications and LTPFS. Statistical analysis included the Kaplan-Meier method, Cox proportional hazards model, competing risk analysis, univariate/multivariate logistic/exact logistic regressions, and the Fisher exact test. Complications were reported according to modified Society of Interventional Radiology guidelines. RESULTS: The median follow-up was 31 months. There was no LTP for MM > 10 mm. Smaller tumor size, increased MM, and prior hepatectomy correlated with longer LTPFS. The major complications occurred following 28 (7%) of 378 procedures. There were no biliary complications in HAI-naive patients, versus 11% in HAI patients (P < .001), of which 7% were major. Biliary complications predictors in HAI patients included biliary dilatation, bevacizumab, and MM > 10 mm. In HAI patients, ablation with 6 to 10 mm and > 10 mm MM resulted in major biliary complication rates of 4% and 21% (P = .0011), with corresponding LTP rates of 24% and 0% (P = .0033). In HAI-naive patients, the LTP rates for 6 to 10 mm and > 10 mm MM were 27% and 0%, respectively. CONCLUSIONS: No LTP was seen for MM > 10 mm. Biliary complications occurred only in HAI patients, especially in those with biliary dilatation, bevacizumab, and MM > 10 mm. In HAI patients, MM of 6 to 10 mm resulted in 76% local tumor control and 4% major biliary complications incidence.
Authors: Emily A Knott; Timothy J Ziemlewicz; Sam J Lubner; John F Swietlik; Sharon M Weber; Annie M Zlevor; Colin Longhurst; J Louis Hinshaw; Meghan G Lubner; Daniel L Mulkerin; Daniel E Abbott; Dustin Deming; Noelle K LoConte; Nataliya Uboha; Allison B Couillard; Shane A Wells; Paul F Laeseke; Marci L Alexander; Fred T Lee Journal: J Gastrointest Oncol Date: 2021-08
Authors: Nikiforos Vasiniotis Kamarinos; Mithat Gonen; Vlasios Sotirchos; Elena Kaye; Elena N Petre; Stephen B Solomon; Joseph P Erinjeri; Etay Ziv; Assen Kirov; Constantinos T Sofocleous Journal: Int J Hyperthermia Date: 2022 Impact factor: 3.753
Authors: Nikiforos Vasiniotis Kamarinos; Efsevia Vakiani; Sho Fujisawa; Mithat Gonen; Ning Fan; Yevgeniy Romin; Richard K G Do; Etay Ziv; Joseph P Erinjeri; Elena N Petre; Vlasios S Sotirchos; Juan C Camacho; Stephen B Solomon; Katia Manova-Todorova; Constantinos T Sofocleous Journal: J Vasc Interv Radiol Date: 2021-11-17 Impact factor: 3.682
Authors: I Kurilova; A Bendet; E K Fung; E N Petre; J L Humm; F E Boas; C H Crane; N Kemeny; T P Kingham; A Cercek; M I D'Angelica; R G H Beets-Tan; C T Sofocleous Journal: Abdom Radiol (NY) Date: 2021-02-19
Authors: Lea Hitpass; Martina Distelmaier; Ulf P Neumann; Wenzel Schöning; Peter Isfort; Sebastian Keil; Christiane K Kuhl; Philipp Bruners; Alexandra Barabasch Journal: Cardiovasc Intervent Radiol Date: 2021-11-10 Impact factor: 2.740
Authors: Kaisa Lehtomäki; Hanna P Stedt; Emerik Osterlund; Timo Muhonen; Leena-Maija Soveri; Päivi Halonen; Tapio K Salminen; Juha Kononen; Raija Kallio; Annika Ålgars; Eetu Heervä; Annamarja Lamminmäki; Aki Uutela; Arno Nordin; Juho Lehto; Tiina Saarto; Harri Sintonen; Pirkko-Liisa Kellokumpu-Lehtinen; Raija Ristamäki; Bengt Glimelius; Helena Isoniemi; Pia Osterlund Journal: Cancers (Basel) Date: 2022-03-28 Impact factor: 6.639